BMN 111

DRUG6 trials

Sponsors

BioMarin Pharmaceutical

Conditions

Achondroplasia

Phase 1

A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult Volunteers

CompletedNCT01590446

BioMarin PharmaceuticalAchondroplasia

Start: 2012-02-29End: 2012-06-30Target: 74Updated: 2012-06-11

Phase 2

A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasia

CompletedNCT02055157

BioMarin PharmaceuticalAchondroplasia

Start: 2014-01-13End: 2017-10-02Updated: 2021-01-15

A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)

Active, not recruitingNCT02724228

BioMarin PharmaceuticalAchondroplasia

Start: 2016-01-26End: 2028-02-01Updated: 2026-03-13

A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia

CompletedNCT03583697

BioMarin PharmaceuticalAchondroplasia

Start: 2018-06-13End: 2022-01-26Updated: 2024-06-13

Phase 3

A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia

CompletedNCT03197766

BioMarin PharmaceuticalAchondroplasia

Start: 2016-12-12End: 2019-10-30Updated: 2022-03-02

An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia

Active, not recruitingNCT03424018

BioMarin PharmaceuticalAchondroplasia

Start: 2017-12-12End: 2031-06-01Updated: 2026-03-13

Related Papers

Long-term vosoritide treatment sustains bone growth and may enhance wellbeing in children with achondroplasia: a plain language summary

Future Rare Diseases2026-06-11

Sustained growth-promoting effects of vosoritide in children with achondroplasia from an ongoing phase 3 extension study.

2024-12-307 citations

Persistent growth-promoting effects of vosoritide in children with achondroplasia are accompanied by improvements in physical and social aspects of health-related quality of life.

2024-09-189 citations

Development of a Weight-Band Dosing Approach for Vosoritide in Children with Achondroplasia Using a Population Pharmacokinetic Model

Clinical Pharmacokinetics2024-04-23

Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial.

2023-11-1839 citations

LBMON196 A Randomized Controlled Trial Of Vosoritide In Infants And Toddlers With Achondroplasia

Journal of the Endocrine Society2022-11-012 citations

Pharmacokinetics and Exposure–Response of Vosoritide in Children with Achondroplasia

Clinical Pharmacokinetics2021-08-2536 citations

Vosoritide Treatment Accelerates Bone Growth in Children with Achondroplasia

Future Rare Diseases2021-08-162 citations

Rationale, design, and methods of a randomized, controlled, open-label clinical trial with open-label extension to investigate the safety of vosoritide in infants, and young children with achondroplasia at risk of requiring cervicomedullary decompression surgery

Science Progress2021-01-0126 citations

C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia

New England Journal of Medicine2019-06-18204 citations